Vicore Pharma announces that the Japanese Ministry of Health and Welfare (MHLW) has granted buloxibutide orphan drug status for the treatment of idiopathic pulmonary fibrosis (IPF). Buloxibutide is a first-in-class angiotensin II type 2 receptor agonist that activates the body's own healing mechanism. Vicore entered into an exclusive licensing agreement with in February 2024 Nippon Shinyaku for development and commercialization in Japan. Orphan drug status entails, for example, reduced fees and extended market exclusivity.
|
Published September 30, 2025
Vicore receives orphan drug status in Japan
Notes
VibroSense Dynamics announces delayed deliveries to China
Acarix reports strong growth in Q3 2025
20 percent weight loss for Eli Lilly's amylin agonist
Stable outlook for AstraZeneca
Camurus lowers full-year forecast
Thor Medical signs supply agreement with Telix
FluoGuide strengthens clinical development management
NEWSLETTER
Upcoming events
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
How European companies can succeed in the Chinese deal market
FDA concerns delay Xspray Pharma's Dasynoc approval again
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Today's news roundup
